Drugs / INT-210
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07616791 | Sep 2025 → Jan 2026 | inflammatory bowel disease | Innatus Therapeutics (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07692165 | Jun 2026 → Jun 2028 expected | ulcerative colitis | Innatus Therapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INT-210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07692165 ↗ |
| Route | Oral | “Oral administration” NCT07616791 ↗ |